<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175825</url>
  </required_header>
  <id_info>
    <org_study_id>N01193</org_study_id>
    <nct_id>NCT00175825</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50
      mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2005</start_date>
  <completion_date type="Actual">June 29, 2006</completion_date>
  <primary_completion_date type="Actual">June 29, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period</measure>
    <time_frame>Baseline, during the 7-week Treatment Period</time_frame>
    <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>A responder was defined as a subject with a &gt;= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Categories of percentage reductions in seizures from baseline were as following: &lt; -25 %; -25 % to &lt;25 %; 25 % to &lt;75 %; 75 % to &lt;100 %; 100 %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Are Seizure Free During the 7-week Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seizure-free Days Per 4 Weeks</measure>
    <time_frame>Baseline, during the 7-week Treatment Period</time_frame>
    <description>A day was considered seizure-free, if no seizure was reported during 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period</measure>
    <time_frame>During the 7-week Treatment Period</time_frame>
    <description>Number of days to first, fifth, and tenth seizure after baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo tablets administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 5 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 20 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period</description>
    <arm_group_label>Brivaracetam 20 mg/day</arm_group_label>
    <arm_group_label>Brivaracetam 5 mg/day</arm_group_label>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
    <other_name>Briviact</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female from 16 to 65 years

          -  Well-characterized focal epilepsy or epileptic syndrome according to the International
             League Against Epilepsy (ILAE) classification

          -  History of partial onset seizures

          -  Subjects having at least 4 partial onset seizures during the 4-week Baseline Period
             and at least 2 partial onset seizures during the 3 months prior to Visit 1

          -  Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a
             stable dose.

        Exclusion Criteria:

          -  Seizure type IA non-motor as only seizure type

          -  Seizures occurring only in clusters

          -  Status epilepticus during the last 2 years before Visit 1

          -  History of cerebrovascular accident (CVA)

          -  Presence of any sign suggesting rapidly progressing brain disorder or brain tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruston</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood Cliffs</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woonsocket</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florianopolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parel Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chichuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valle Oriente Garza Garcia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>India</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Panama</country>
  </removed_countries>
  <link>
    <url>https://www.briviact.com/briviact-PI.pdf?v=1479491757</url>
    <description>Product Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139-51. doi: 10.1111/epi.13416. Epub 2016 Jun 6.</citation>
    <PMID>27265725</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>October 26, 2017</results_first_submitted>
  <results_first_submitted_qc>August 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2018</results_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy: partial onset seizures</keyword>
  <keyword>brivaracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in November 2005 and concluded in June 2006.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the Intention-to-treat (ITT) Set. 210 subjects were initially randomized, 2 subjects discontinued due to Lost to Follow-Up before first study drug intake.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo tablets administered twice a day</description>
        </group>
        <group group_id="P2">
          <title>Brivaracetam 5 mg/Day</title>
          <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
        </group>
        <group group_id="P3">
          <title>Brivaracetam 20 mg/Day</title>
          <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
        </group>
        <group group_id="P4">
          <title>Brivaracetam 50 mg/Day</title>
          <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Intention-to-Treat (ITT) Set.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo tablets administered twice a day</description>
        </group>
        <group group_id="B2">
          <title>Brivaracetam 5 mg/Day</title>
          <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
        </group>
        <group group_id="B3">
          <title>Brivaracetam 20 mg/Day</title>
          <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
        </group>
        <group group_id="B4">
          <title>Brivaracetam 50 mg/Day</title>
          <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
        </group>
        <group group_id="B5">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.59" spread="11.26"/>
                    <measurement group_id="B2" value="32.72" spread="12.16"/>
                    <measurement group_id="B3" value="35.31" spread="13.66"/>
                    <measurement group_id="B4" value="30.92" spread="11.57"/>
                    <measurement group_id="B5" value="33.15" spread="12.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period</title>
        <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
        <time_frame>Baseline, during the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period</title>
          <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" lower_limit="-42.99" upper_limit="12.04"/>
                    <measurement group_id="O2" value="-29.91" lower_limit="-53.33" upper_limit="-3.83"/>
                    <measurement group_id="O3" value="-42.56" lower_limit="-67.92" upper_limit="0.44"/>
                    <measurement group_id="O4" value="-53.04" lower_limit="-69.33" upper_limit="-19.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period</title>
        <description>Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period</title>
          <description>Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.</description>
          <units>seizures per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" lower_limit="1.30" upper_limit="4.22"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.38" upper_limit="5.00"/>
                    <measurement group_id="O3" value="2.50" lower_limit="1.50" upper_limit="6.06"/>
                    <measurement group_id="O4" value="1.99" lower_limit="1.36" upper_limit="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="0.88" upper_limit="3.50"/>
                    <measurement group_id="O2" value="1.61" lower_limit="0.75" upper_limit="4.34"/>
                    <measurement group_id="O3" value="1.70" lower_limit="0.59" upper_limit="3.97"/>
                    <measurement group_id="O4" value="0.92" lower_limit="0.69" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period</title>
        <description>Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period</title>
          <description>Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
          <units>seizures per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" lower_limit="-1.18" upper_limit="0.19"/>
                    <measurement group_id="O2" value="-0.66" lower_limit="-1.19" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.84" lower_limit="-2.21" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="-0.92" lower_limit="-2.44" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period</title>
        <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period</title>
          <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
          <units>seizures per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" lower_limit="-1.18" upper_limit="0.19"/>
                    <measurement group_id="O2" value="-0.66" lower_limit="-1.19" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.80" lower_limit="-2.21" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="-0.92" lower_limit="-2.44" upper_limit="-0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period</title>
        <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period</title>
          <description>Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.</description>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.35" lower_limit="-43.61" upper_limit="12.00"/>
                    <measurement group_id="O2" value="-29.91" lower_limit="-53.33" upper_limit="-3.83"/>
                    <measurement group_id="O3" value="-41.57" lower_limit="-65.31" upper_limit="0.44"/>
                    <measurement group_id="O4" value="-53.05" lower_limit="-69.33" upper_limit="-22.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period</title>
        <description>A responder was defined as a subject with a &gt;= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period</title>
          <description>A responder was defined as a subject with a &gt;= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="44.2"/>
                    <measurement group_id="O4" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period</title>
        <description>Categories of percentage reductions in seizures from baseline were as following: &lt; -25 %; -25 % to &lt;25 %; 25 % to &lt;75 %; 75 % to &lt;100 %; 100 %.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period</title>
          <description>Categories of percentage reductions in seizures from baseline were as following: &lt; -25 %; -25 % to &lt;25 %; 25 % to &lt;75 %; 75 % to &lt;100 %; 100 %.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; -25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="9.6"/>
                    <measurement group_id="O4" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-25% to &lt;25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="38.0"/>
                    <measurement group_id="O3" value="30.8"/>
                    <measurement group_id="O4" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25% to &lt;75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="40.4"/>
                    <measurement group_id="O4" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75% to &lt;100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="11.5"/>
                    <measurement group_id="O4" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Are Seizure Free During the 7-week Treatment Period</title>
        <description>A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Are Seizure Free During the 7-week Treatment Period</title>
          <description>A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Completed the Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued from the Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seizure-free Days Per 4 Weeks</title>
        <description>A day was considered seizure-free, if no seizure was reported during 24 hours.</description>
        <time_frame>Baseline, during the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seizure-free Days Per 4 Weeks</title>
          <description>A day was considered seizure-free, if no seizure was reported during 24 hours.</description>
          <units>Days/4 Weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.66" lower_limit="16.57" upper_limit="24.57"/>
                    <measurement group_id="O2" value="22.86" lower_limit="15.43" upper_limit="25.14"/>
                    <measurement group_id="O3" value="22.84" lower_limit="18.57" upper_limit="25.71"/>
                    <measurement group_id="O4" value="24.65" lower_limit="21.14" upper_limit="25.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period</title>
        <description>Number of days to first, fifth, and tenth seizure after baseline.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period</title>
          <description>Number of days to first, fifth, and tenth seizure after baseline.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of days to first seizure after baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="7.0" lower_limit="4.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of days to fifth seizure after baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="13.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="17.0" upper_limit="27.0"/>
                    <measurement group_id="O3" value="18.5" lower_limit="14.0" upper_limit="29.0"/>
                    <measurement group_id="O4" value="32.5" lower_limit="23.0" upper_limit="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of days to tenth seizure after baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="23.0" upper_limit="45.0"/>
                    <measurement group_id="O2" value="38.0" lower_limit="27.0" upper_limit="NA">upper limit is not available</measurement>
                    <measurement group_id="O3" value="39.0" lower_limit="23.0" upper_limit="NA">upper limit is not available</measurement>
                    <measurement group_id="O4" value="57.0" lower_limit="49.0" upper_limit="NA">upper limit is not available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period</title>
        <description>Calculated as 7-day partial onset seizure frequency.</description>
        <time_frame>During the 7-week Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 5 mg/Day</title>
            <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period</title>
          <description>Calculated as 7-day partial onset seizure frequency.</description>
          <units>Seizures per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="0.88" upper_limit="3.50"/>
                    <measurement group_id="O2" value="1.61" lower_limit="0.75" upper_limit="4.34"/>
                    <measurement group_id="O3" value="1.55" lower_limit="0.57" upper_limit="3.83"/>
                    <measurement group_id="O4" value="0.92" lower_limit="0.69" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA with baseline seizure frequency per week and each of the stratification factors as independent variables.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.240</p_value>
            <method>ANCOVA</method>
            <param_type>Percent reduction over Placebo</param_type>
            <param_value>9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>24.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA with baseline seizure frequency per week and each of the stratification factors as independent variables.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.062</p_value>
            <method>ANCOVA</method>
            <param_type>Percent reduction over Placebo</param_type>
            <param_value>14.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA with baseline seizure frequency per week and each of the stratification factors as independent variables.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Percent reduction over Placebo</param_type>
            <param_value>22.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.6</ci_lower_limit>
            <ci_upper_limit>34.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Baseline until Safety Visit (up to 3 months).</time_frame>
      <desc>Adverse Events refer to the Safety Population consisting of all subjects who were dispensed medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo tablets administered twice a day</description>
        </group>
        <group group_id="E2">
          <title>Brivaracetam 5 mg/Day</title>
          <description>Brivaracetam 5 mg/day, 2.5 mg administered twice a day</description>
        </group>
        <group group_id="E3">
          <title>Brivaracetam 20 mg/Day</title>
          <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
        </group>
        <group group_id="E4">
          <title>Brivaracetam 50 mg/Day</title>
          <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

